Development of Novel Paclitaxel-Loaded ZIF-8 Metal-Organic Framework Nanoparticles Modified with Peptide Dimers and an Evaluation of Its Inhibitory Effect against Prostate Cancer Cells

Prostate cancer (PC) is one of the common malignant tumors of the male genitourinary system. Here, we constructed PTX@ZIF-8, which is a metal-organic-framework-encapsulated drug delivery nanoparticle with paclitaxel (PTX) as a model drug, and further modified the synthesized peptide dimer (Di-PEG200...

Full description

Saved in:
Bibliographic Details
Published inPharmaceutics Vol. 15; no. 7; p. 1874
Main Authors Zhao, Heming, Gong, Liming, Wu, Hao, Liu, Chao, Liu, Yanhong, Xiao, Congcong, Liu, Chenfei, Chen, Liqing, Jin, Mingji, Gao, Zhonggao, Guan, Youyan, Huang, Wei
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.07.2023
MDPI
Subjects
Analysis
Androgens
Apoptosis
Cancer
Cancer therapies
Care and treatment
Cell culture
Chemotherapy
Clinical medicine
Drug delivery systems
Drugs
Efficiency
Ions
metal-organic framework
Nanoparticles
NMR
Nuclear magnetic resonance
Paclitaxel
Particle size
peptide dimer
Peptides
Polypeptides
Porous materials
Prevention
Prostate cancer
Tumors
Vehicles
Zinc
Japan
China
Beijing China
United States > US
paclitaxel
prostate cancer
peptide dimer
metal-organic framework
Online AccessGet full text

Cover

Abstract Prostate cancer (PC) is one of the common malignant tumors of the male genitourinary system. Here, we constructed PTX@ZIF-8, which is a metal-organic-framework-encapsulated drug delivery nanoparticle with paclitaxel (PTX) as a model drug, and further modified the synthesized peptide dimer (Di-PEG2000-COOH) onto the surface of PTX@ZIF-8 to prepare a nanotargeted drug delivery system (Di-PEG@PTX@ZIF-8) for the treatment of prostate cancer. This study investigated the morphology, particle size distribution, zeta potential, drug loading, encapsulation rate, stability, in vitro release behavior, and cytotoxicity of this targeted drug delivery system, and explored the uptake of Di-PEG@PTX@ZIF-8 by human prostate cancer Lncap cells at the in vitro cellular level, as well as the proliferation inhibition and promotion of apoptosis of Lncap cells by the composite nanoparticles. The results suggest that Di-PEG@PTX@ZIF-8, as a zeolitic imidazolate frameworks-8-loaded paclitaxel nanoparticle, has promising potential for the treatment of prostate cancer, which may provide a novel strategy for the delivery system targeting prostate cancer.
AbstractList Prostate cancer (PC) is one of the common malignant tumors of the male genitourinary system. Here, we constructed PTX@ZIF-8, which is a metal-organic-framework-encapsulated drug delivery nanoparticle with paclitaxel (PTX) as a model drug, and further modified the synthesized peptide dimer (Di-PEG2000-COOH) onto the surface of PTX@ZIF-8 to prepare a nanotargeted drug delivery system (Di-PEG@PTX@ZIF-8) for the treatment of prostate cancer. This study investigated the morphology, particle size distribution, zeta potential, drug loading, encapsulation rate, stability, in vitro release behavior, and cytotoxicity of this targeted drug delivery system, and explored the uptake of Di-PEG@PTX@ZIF-8 by human prostate cancer Lncap cells at the in vitro cellular level, as well as the proliferation inhibition and promotion of apoptosis of Lncap cells by the composite nanoparticles. The results suggest that Di-PEG@PTX@ZIF-8, as a zeolitic imidazolate frameworks-8-loaded paclitaxel nanoparticle, has promising potential for the treatment of prostate cancer, which may provide a novel strategy for the delivery system targeting prostate cancer.
Prostate cancer (PC) is one of the common malignant tumors of the male genitourinary system. Here, we constructed PTX@ZIF-8, which is a metal-organic-framework-encapsulated drug delivery nanoparticle with paclitaxel (PTX) as a model drug, and further modified the synthesized peptide dimer (Di-PEG2000-COOH) onto the surface of PTX@ZIF-8 to prepare a nanotargeted drug delivery system (Di-PEG@PTX@ZIF-8) for the treatment of prostate cancer. This study investigated the morphology, particle size distribution, zeta potential, drug loading, encapsulation rate, stability, in vitro release behavior, and cytotoxicity of this targeted drug delivery system, and explored the uptake of Di-PEG@PTX@ZIF-8 by human prostate cancer Lncap cells at the in vitro cellular level, as well as the proliferation inhibition and promotion of apoptosis of Lncap cells by the composite nanoparticles. The results suggest that Di-PEG@PTX@ZIF-8, as a zeolitic imidazolate frameworks-8-loaded paclitaxel nanoparticle, has promising potential for the treatment of prostate cancer, which may provide a novel strategy for the delivery system targeting prostate cancer.Prostate cancer (PC) is one of the common malignant tumors of the male genitourinary system. Here, we constructed PTX@ZIF-8, which is a metal-organic-framework-encapsulated drug delivery nanoparticle with paclitaxel (PTX) as a model drug, and further modified the synthesized peptide dimer (Di-PEG2000-COOH) onto the surface of PTX@ZIF-8 to prepare a nanotargeted drug delivery system (Di-PEG@PTX@ZIF-8) for the treatment of prostate cancer. This study investigated the morphology, particle size distribution, zeta potential, drug loading, encapsulation rate, stability, in vitro release behavior, and cytotoxicity of this targeted drug delivery system, and explored the uptake of Di-PEG@PTX@ZIF-8 by human prostate cancer Lncap cells at the in vitro cellular level, as well as the proliferation inhibition and promotion of apoptosis of Lncap cells by the composite nanoparticles. The results suggest that Di-PEG@PTX@ZIF-8, as a zeolitic imidazolate frameworks-8-loaded paclitaxel nanoparticle, has promising potential for the treatment of prostate cancer, which may provide a novel strategy for the delivery system targeting prostate cancer.
Prostate cancer (PC) is one of the common malignant tumors of the male genitourinary system. Here, we constructed PTX@ZIF-8, which is a metal-organic-framework-encapsulated drug delivery nanoparticle with paclitaxel (PTX) as a model drug, and further modified the synthesized peptide dimer (Di-PEG[sub.2000]-COOH) onto the surface of PTX@ZIF-8 to prepare a nanotargeted drug delivery system (Di-PEG@PTX@ZIF-8) for the treatment of prostate cancer. This study investigated the morphology, particle size distribution, zeta potential, drug loading, encapsulation rate, stability, in vitro release behavior, and cytotoxicity of this targeted drug delivery system, and explored the uptake of Di-PEG@PTX@ZIF-8 by human prostate cancer Lncap cells at the in vitro cellular level, as well as the proliferation inhibition and promotion of apoptosis of Lncap cells by the composite nanoparticles. The results suggest that Di-PEG@PTX@ZIF-8, as a zeolitic imidazolate frameworks-8-loaded paclitaxel nanoparticle, has promising potential for the treatment of prostate cancer, which may provide a novel strategy for the delivery system targeting prostate cancer.
Prostate cancer (PC) is one of the common malignant tumors of the male genitourinary system. Here, we constructed PTX@ZIF-8, which is a metal-organic-framework-encapsulated drug delivery nanoparticle with paclitaxel (PTX) as a model drug, and further modified the synthesized peptide dimer (Di-PEG -COOH) onto the surface of PTX@ZIF-8 to prepare a nanotargeted drug delivery system (Di-PEG@PTX@ZIF-8) for the treatment of prostate cancer. This study investigated the morphology, particle size distribution, zeta potential, drug loading, encapsulation rate, stability, in vitro release behavior, and cytotoxicity of this targeted drug delivery system, and explored the uptake of Di-PEG@PTX@ZIF-8 by human prostate cancer Lncap cells at the in vitro cellular level, as well as the proliferation inhibition and promotion of apoptosis of Lncap cells by the composite nanoparticles. The results suggest that Di-PEG@PTX@ZIF-8, as a zeolitic imidazolate frameworks-8-loaded paclitaxel nanoparticle, has promising potential for the treatment of prostate cancer, which may provide a novel strategy for the delivery system targeting prostate cancer.
Prostate cancer (PC) is one of the common malignant tumors of the male genitourinary system. Here, we constructed PTX@ZIF-8, which is a metal-organic-framework-encapsulated drug delivery nanoparticle with paclitaxel (PTX) as a model drug, and further modified the synthesized peptide dimer (Di-PEG 2000 -COOH) onto the surface of PTX@ZIF-8 to prepare a nanotargeted drug delivery system (Di-PEG@PTX@ZIF-8) for the treatment of prostate cancer. This study investigated the morphology, particle size distribution, zeta potential, drug loading, encapsulation rate, stability, in vitro release behavior, and cytotoxicity of this targeted drug delivery system, and explored the uptake of Di-PEG@PTX@ZIF-8 by human prostate cancer Lncap cells at the in vitro cellular level, as well as the proliferation inhibition and promotion of apoptosis of Lncap cells by the composite nanoparticles. The results suggest that Di-PEG@PTX@ZIF-8, as a zeolitic imidazolate frameworks-8-loaded paclitaxel nanoparticle, has promising potential for the treatment of prostate cancer, which may provide a novel strategy for the delivery system targeting prostate cancer.
Audience Academic
Author Liu, Chenfei
Chen, Liqing
Liu, Chao
Gao, Zhonggao
Wu, Hao
Zhao, Heming
Guan, Youyan
Huang, Wei
Liu, Yanhong
Jin, Mingji
Gong, Liming
Xiao, Congcong
AuthorAffiliation 3 Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
2 Department of Pharmacy, Yanbian University, Yanji 133000, China; wuhao931230@163.com
1 State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmaceutics, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China; zhaoheming@imm.ac.cn (H.Z.); dawngong@163.com (L.G.); chaoliu@imm.ac.cn (C.L.); liuyanhong@imm.ac.cn (Y.L.); xiaocongcong@imm.ac.cn (C.X.); liuchenfei@imm.ac.cn (C.L.); chenliqing@imm.ac.cn (L.C.); jinmingji@imm.ac.cn (M.J.)
AuthorAffiliation_xml – name: 3 Department of Urology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China
– name: 2 Department of Pharmacy, Yanbian University, Yanji 133000, China; wuhao931230@163.com
– name: 1 State Key Laboratory of Bioactive Substance and Function of Natural Medicines, Department of Pharmaceutics, Institute of Materia Medica, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100050, China; zhaoheming@imm.ac.cn (H.Z.); dawngong@163.com (L.G.); chaoliu@imm.ac.cn (C.L.); liuyanhong@imm.ac.cn (Y.L.); xiaocongcong@imm.ac.cn (C.X.); liuchenfei@imm.ac.cn (C.L.); chenliqing@imm.ac.cn (L.C.); jinmingji@imm.ac.cn (M.J.)
Author_xml – sequence: 1
  givenname: Heming
  surname: Zhao
  fullname: Zhao, Heming
– sequence: 2
  givenname: Liming
  orcidid: 0000-0002-8163-099X
  surname: Gong
  fullname: Gong, Liming
– sequence: 3
  givenname: Hao
  surname: Wu
  fullname: Wu, Hao
– sequence: 4
  givenname: Chao
  orcidid: 0000-0001-5236-0102
  surname: Liu
  fullname: Liu, Chao
– sequence: 5
  givenname: Yanhong
  surname: Liu
  fullname: Liu, Yanhong
– sequence: 6
  givenname: Congcong
  surname: Xiao
  fullname: Xiao, Congcong
– sequence: 7
  givenname: Chenfei
  surname: Liu
  fullname: Liu, Chenfei
– sequence: 8
  givenname: Liqing
  surname: Chen
  fullname: Chen, Liqing
– sequence: 9
  givenname: Mingji
  surname: Jin
  fullname: Jin, Mingji
– sequence: 10
  givenname: Zhonggao
  surname: Gao
  fullname: Gao, Zhonggao
– sequence: 11
  givenname: Youyan
  surname: Guan
  fullname: Guan, Youyan
– sequence: 12
  givenname: Wei
  surname: Huang
  fullname: Huang, Wei
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37514059$$D View this record in MEDLINE/PubMed
BookMark eNp9Ul1v0zAUjdAQG2U_AWSJF14y7DiuY_GApq6FSvt6gBderFvnpvVI7GK7G_tn_DxctsE2TTiynNjnnOtzc14WO847LIrXjB5wruj79QrCAAY3yZrIBJWskfWzYo8ppcpaVXzn3vtusR_jBc2Dc9Zw9aLY5VKwmgq1V_w6wkvs_XpAl4jvyKnPn-QcTG8T_MS-PPbQYku-zWdlQ04wQV-ehSU4a8gswIBXPnwnp-D8GkK-TY-RnPjWdjaTrmxakXNcJ9siObIDhkjAtXmS6SX0G0jWu23VeYpk7lZ2YZMP12TadWgSgSVYFxM5Dz4mSEgm4AwGMsG-j6-K5x30Efdv11HxdTb9MvlcHp99mk8Oj0sjJE9lhUqZTskFZxJrgVKCYMawsVQSWt7wTiwqQwUI3iBI2jEGTW4OawVlTAAfFfMb3dbDhV4HO0C41h6s_rPhw1LfGtcdb4VsODdqDPWihgYrUTFFZasWNcMma3280VpvFgO2Jvc8QP9A9OGJsyu99Jea0XxTJVlWeHerEPyPDcakBxtN7gc49Juoq6auqRJiPM7Qt4-gF34TXO7VFsUZpRWn_1BLyA6s63wubLai-lAKxRrVZEej4uAJVH5aHKzJ2exs3n9AeHPf6V-Ld8HLgA83AJN_bgzYaZMDt81DVrZ9dqy3SddPJj2zxSP2XYH_834Dgo4HbA
CitedBy_id crossref_primary_10_1002_bab_2689
crossref_primary_10_3390_biomedicines12010202
crossref_primary_10_1016_j_nxmate_2025_100611
crossref_primary_10_3390_pharmaceutics15092208
crossref_primary_10_1002_slct_202304443
crossref_primary_10_1080_09205063_2024_2364533
crossref_primary_10_1016_j_ijbiomac_2024_137776
crossref_primary_10_1021_acsami_3c16534
crossref_primary_10_1007_s10924_024_03382_7
crossref_primary_10_1016_j_ijbiomac_2024_129391
crossref_primary_10_1007_s12032_024_02567_3
crossref_primary_10_3390_ijms26062633
crossref_primary_10_1007_s00396_024_05357_5
crossref_primary_10_1007_s10876_024_02739_1
Cites_doi 10.1021/jacs.5b11720
10.1126/sciadv.aay9751
10.1016/j.cclet.2022.01.021
10.1016/j.ajur.2018.11.005
10.2147/IJN.S136032
10.1200/JCO.2014.58.2973
10.1186/2191-219X-2-8
10.1016/j.drup.2021.100754
10.1158/0008-5472.CAN-06-1520
10.1021/nn2048526
10.1016/j.biopha.2023.114392
10.1039/D3TB00027C
10.1126/sciadv.aaz6108
10.1007/s12274-017-1874-y
10.1080/10408347.2017.1416283
10.1038/nbt1197-1261
10.1002/pros.23772
10.3390/pharmaceutics12070661
10.1016/j.apsb.2021.03.019
10.3390/ijms21082991
10.1021/acsami.6b14390
10.1016/j.biomaterials.2013.11.088
10.1039/c2dt30357d
10.1517/14728222.9.3.561
10.1016/j.clgc.2020.05.003
10.1016/j.addr.2017.02.003
10.1016/j.jconrel.2014.05.035
10.1053/j.semnuclmed.2016.07.002
10.1186/1743-7075-11-30
10.3390/pharmaceutics14050964
10.1021/nn406590q
ContentType Journal Article
Copyright COPYRIGHT 2023 MDPI AG
2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2023 by the authors. 2023
Copyright_xml – notice: COPYRIGHT 2023 MDPI AG
– notice: 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2023 by the authors. 2023
DBID AAYXX
CITATION
NPM
3V.
7XB
8FK
8G5
ABUWG
AFKRA
AZQEC
BENPR
CCPQU
DWQXO
GNUQQ
GUQSH
M2O
MBDVC
PHGZM
PHGZT
PIMPY
PKEHL
PQEST
PQQKQ
PQUKI
PRINS
Q9U
7X8
5PM
DOA
DOI 10.3390/pharmaceutics15071874
DatabaseName CrossRef
PubMed
ProQuest Central (Corporate)
ProQuest Central (purchase pre-March 2016)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Research Library
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
ProQuest Central Essentials
ProQuest Central
ProQuest One
ProQuest Central Korea
ProQuest Central Student
ProQuest Research Library
Research Library
Research Library (Corporate)
ProQuest Central Premium
ProQuest One Academic (New)
Publicly Available Content Database (ProQuest)
ProQuest One Academic Middle East (New)
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
ProQuest Central Basic
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle CrossRef
PubMed
Publicly Available Content Database
Research Library Prep
ProQuest Central Student
ProQuest One Academic Middle East (New)
ProQuest Central Basic
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Central (Alumni Edition)
ProQuest One Community College
Research Library (Alumni Edition)
ProQuest Central China
ProQuest Central
ProQuest One Academic UKI Edition
ProQuest Central Korea
ProQuest Research Library
ProQuest Central (New)
ProQuest One Academic
ProQuest One Academic (New)
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList CrossRef
MEDLINE - Academic

PubMed


Publicly Available Content Database
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 3
  dbid: BENPR
  name: ProQuest Central
  url: https://www.proquest.com/central
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Pharmacy, Therapeutics, & Pharmacology
EISSN 1999-4923
ExternalDocumentID oai_doaj_org_article_f3d57833c96a4b4a8e2521907d9b41e8
PMC10383971
A759189883
37514059
10_3390_pharmaceutics15071874
Genre Journal Article
GeographicLocations Japan
China
Beijing China
United States--US
GeographicLocations_xml – name: China
– name: Japan
– name: Beijing China
– name: United States--US
GrantInformation_xml – fundername: Bethune Cancer Basic Research Program Project (2021)
  grantid: BCF-NH-ZL-202203-002, China
– fundername: CSCO Navigation Cancer Research Fund
  grantid: Y-2019AZQN-0398, China
– fundername: CAMS Innovation Fund for Medical Sciences (CIFMS)
  grantid: 2021-I2M-1-026, China
– fundername: Bethune Urinary Cancer Special Research Fund
  grantid: mnzl202014, China
– fundername: National Natural Science Foundation of China
  grantid: No. 82073778, China
– fundername: National Natural Science Foundation of China
  grantid: 82073778
– fundername: Bethune Cancer Basic Research Program Project
  grantid: BCF-NH-ZL-202203-002
– fundername: CAMS Innovation Fund for Medical Sciences (CIFMS)
  grantid: 2021-I2M-1-026
– fundername: CSCO Navigation Cancer Research Fund
  grantid: Y-2019AZQN-0398
– fundername: Bethune Urinary Cancer Special Research Fund
  grantid: mnzl202014
GroupedDBID ---
53G
5VS
8G5
AADQD
AAYXX
ABDBF
ABUWG
ACGFO
ACIHN
ACUHS
AEAQA
AFKRA
AFZYC
ALMA_UNASSIGNED_HOLDINGS
AZQEC
BENPR
BPHCQ
CCPQU
CITATION
DIK
DWQXO
EBD
ESX
F5P
FD6
GNUQQ
GROUPED_DOAJ
GUQSH
GX1
HH5
HYE
IAO
IHR
ITC
KQ8
M2O
M48
MK0
MODMG
M~E
OK1
P6G
PGMZT
PHGZM
PHGZT
PIMPY
PQQKQ
PROAC
RNS
RPM
TR2
TUS
NPM
PMFND
3V.
7XB
8FK
MBDVC
PKEHL
PQEST
PQUKI
PRINS
Q9U
7X8
5PM
PUEGO
ID FETCH-LOGICAL-c573t-2e99cf97b317e45e77a51cc16797ad383f5b2c05a538ea70f11a85141d50115a3
IEDL.DBID BENPR
ISSN 1999-4923
IngestDate Wed Aug 27 01:26:54 EDT 2025
Thu Aug 21 18:36:38 EDT 2025
Fri Jul 11 01:38:46 EDT 2025
Sun Jun 29 14:44:50 EDT 2025
Tue Jun 17 20:43:18 EDT 2025
Tue Jun 10 21:24:39 EDT 2025
Mon Jul 21 06:00:31 EDT 2025
Thu Apr 24 22:56:48 EDT 2025
Tue Jul 01 00:36:59 EDT 2025
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 7
Keywords paclitaxel
prostate cancer
peptide dimer
metal-organic framework
Language English
License https://creativecommons.org/licenses/by/4.0
Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c573t-2e99cf97b317e45e77a51cc16797ad383f5b2c05a538ea70f11a85141d50115a3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
These authors contributed equally to this work.
ORCID 0000-0001-5236-0102
0000-0002-8163-099X
OpenAccessLink https://www.proquest.com/docview/2843100230?pq-origsite=%requestingapplication%
PMID 37514059
PQID 2843100230
PQPubID 2032349
ParticipantIDs doaj_primary_oai_doaj_org_article_f3d57833c96a4b4a8e2521907d9b41e8
pubmedcentral_primary_oai_pubmedcentral_nih_gov_10383971
proquest_miscellaneous_2844095566
proquest_journals_2843100230
gale_infotracmisc_A759189883
gale_infotracacademiconefile_A759189883
pubmed_primary_37514059
crossref_citationtrail_10_3390_pharmaceutics15071874
crossref_primary_10_3390_pharmaceutics15071874
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-07-01
PublicationDateYYYYMMDD 2023-07-01
PublicationDate_xml – month: 07
  year: 2023
  text: 2023-07-01
  day: 01
PublicationDecade 2020
PublicationPlace Switzerland
PublicationPlace_xml – name: Switzerland
– name: Basel
PublicationTitle Pharmaceutics
PublicationTitleAlternate Pharmaceutics
PublicationYear 2023
Publisher MDPI AG
MDPI
Publisher_xml – name: MDPI AG
– name: MDPI
References Sun (ref_16) 2012; 41
Adashek (ref_30) 2020; 18
Wrighton (ref_18) 1997; 15
Li (ref_17) 2018; 11
He (ref_11) 2021; 11
Alves (ref_9) 2018; 48
Wu (ref_24) 2017; 12
Slovin (ref_28) 2005; 9
Zheng (ref_15) 2016; 138
Wang (ref_12) 2023; 34
Sun (ref_10) 2023; 11
Dong (ref_4) 2019; 6
Barve (ref_5) 2014; 187
Zhuang (ref_13) 2014; 8
Sofias (ref_6) 2017; 122
Hashemi (ref_3) 2023; 160
Liu (ref_8) 2017; 9
Borre (ref_29) 2016; 46
Fournier (ref_19) 2012; 2
Cai (ref_23) 2014; 35
Yang (ref_25) 2012; 6
ref_22
Das (ref_7) 2021; 55
ref_20
Zhuang (ref_31) 2020; 6
Mandair (ref_1) 2014; 11
Xue (ref_27) 2019; 79
He (ref_14) 2020; 6
Klotz (ref_2) 2015; 33
ref_26
Aggarwal (ref_21) 2006; 66
References_xml – volume: 138
  start-page: 962
  year: 2016
  ident: ref_15
  article-title: One-pot Synthesis of Metal-Organic Frameworks with Encapsulated Target Molecules and Their Applications for Controlled Drug Delivery
  publication-title: J. Am. Chem. Soc.
  doi: 10.1021/jacs.5b11720
– volume: 6
  start-page: eaay9751
  year: 2020
  ident: ref_14
  article-title: Highly bioactive zeolitic imidazolate framework-8-capped nanotherapeutics for efficient reversal of reperfusion-induced injury in ischemic stroke
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.aay9751
– volume: 34
  start-page: 107128
  year: 2023
  ident: ref_12
  article-title: Enhanced oxygen reduction reaction performance of Co@N–C derived from metal-organic frameworks ZIF-67 via a continuous microchannel reactor
  publication-title: Chin. Chem. Lett.
  doi: 10.1016/j.cclet.2022.01.021
– volume: 6
  start-page: 26
  year: 2019
  ident: ref_4
  article-title: Metastatic prostate cancer remains incurable, why?
  publication-title: Asian J. Urol.
  doi: 10.1016/j.ajur.2018.11.005
– volume: 12
  start-page: 5313
  year: 2017
  ident: ref_24
  article-title: Paclitaxel-loaded and A10-3.2 aptamer-targeted poly(lactide-co-glycolic acid) nanobubbles for ultrasound imaging and therapy of prostate cancer
  publication-title: Int. J. Nanomed.
  doi: 10.2147/IJN.S136032
– volume: 33
  start-page: 1151
  year: 2015
  ident: ref_2
  article-title: Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: A secondary analysis of the PR-7 trial of intermittent versus continuous ADT
  publication-title: J. Clin. Oncol.
  doi: 10.1200/JCO.2014.58.2973
– volume: 2
  start-page: 8
  year: 2012
  ident: ref_19
  article-title: Comparative study of 64Cu/NOTA-[D-Tyr6,betaAla11,Thi13,Nle14]BBN(6-14) monomer and dimers for prostate cancer PET imaging
  publication-title: EJNMMI Res.
  doi: 10.1186/2191-219X-2-8
– volume: 55
  start-page: 100754
  year: 2021
  ident: ref_7
  article-title: Therapeutic strategies to overcome taxane resistance in cancer
  publication-title: Drug Resist. Updates
  doi: 10.1016/j.drup.2021.100754
– volume: 66
  start-page: 9171
  year: 2006
  ident: ref_21
  article-title: A dimeric peptide that binds selectively to prostate-specific membrane antigen and inhibits its enzymatic activity
  publication-title: Cancer Res.
  doi: 10.1158/0008-5472.CAN-06-1520
– volume: 6
  start-page: 1795
  year: 2012
  ident: ref_25
  article-title: Cooperative dual-activity targeted nanomedicine for specific and effective prostate cancer therapy
  publication-title: ACS Nano
  doi: 10.1021/nn2048526
– volume: 160
  start-page: 114392
  year: 2023
  ident: ref_3
  article-title: Paclitaxel and docetaxel resistance in prostate cancer: Molecular mechanisms and possible therapeutic strategies
  publication-title: Biomed. Pharmacother.
  doi: 10.1016/j.biopha.2023.114392
– volume: 11
  start-page: 3273
  year: 2023
  ident: ref_10
  article-title: Nanoscale MOFs in nanomedicine applications: From drug delivery to therapeutic agents
  publication-title: J. Mater. Chem. B
  doi: 10.1039/D3TB00027C
– volume: 6
  start-page: eaaz6108
  year: 2020
  ident: ref_31
  article-title: Targeted gene silencing in vivo by platelet membrane-coated metal-organic framework nanoparticles
  publication-title: Sci. Adv.
  doi: 10.1126/sciadv.aaz6108
– volume: 11
  start-page: 3294
  year: 2018
  ident: ref_17
  article-title: Coordination-responsive drug release inside gold nanorod@metal-organic framework core–shell nanostructures for near-infrared-induced synergistic chemo-photothermal therapy
  publication-title: Nano Res.
  doi: 10.1007/s12274-017-1874-y
– volume: 48
  start-page: 110
  year: 2018
  ident: ref_9
  article-title: Characteristics, Properties and Analytical Methods of Paclitaxel: A Review
  publication-title: Crit. Rev. Anal. Chem.
  doi: 10.1080/10408347.2017.1416283
– volume: 15
  start-page: 1261
  year: 1997
  ident: ref_18
  article-title: Increased potency of an erythropoietin peptide mimetic through covalent dimerization
  publication-title: Nat. Biotechnol.
  doi: 10.1038/nbt1197-1261
– volume: 79
  start-page: 647
  year: 2019
  ident: ref_27
  article-title: Zinc promotes prostate cancer cell chemosensitivity to paclitaxel by inhibiting epithelial-mesenchymal transition and inducing apoptosis
  publication-title: Prostate
  doi: 10.1002/pros.23772
– ident: ref_20
  doi: 10.3390/pharmaceutics12070661
– volume: 11
  start-page: 2362
  year: 2021
  ident: ref_11
  article-title: Metal-organic frameworks for advanced drug delivery
  publication-title: Acta Pharm. Sin. B
  doi: 10.1016/j.apsb.2021.03.019
– ident: ref_26
  doi: 10.3390/ijms21082991
– volume: 9
  start-page: 7424
  year: 2017
  ident: ref_8
  article-title: Biomimetic Human Serum Albumin Nanoparticle for Efficiently Targeting Therapy to Metastatic Breast Cancers
  publication-title: ACS Appl. Mater. Interfaces
  doi: 10.1021/acsami.6b14390
– volume: 35
  start-page: 2283
  year: 2014
  ident: ref_23
  article-title: Hydrophobic penetrating peptide PFVYLI-modified stealth liposomes for doxorubicin delivery in breast cancer therapy
  publication-title: Biomaterials
  doi: 10.1016/j.biomaterials.2013.11.088
– volume: 41
  start-page: 6906
  year: 2012
  ident: ref_16
  article-title: Zeolitic Imidazolate framework-8 as efficient pH-sensitive drug delivery vehicle
  publication-title: Dalton Trans.
  doi: 10.1039/c2dt30357d
– volume: 9
  start-page: 561
  year: 2005
  ident: ref_28
  article-title: Targeting novel antigens for prostate cancer treatment: Focus on prostate-specific membrane antigen
  publication-title: Expert Opin. Ther. Targets
  doi: 10.1517/14728222.9.3.561
– volume: 18
  start-page: 425
  year: 2020
  ident: ref_30
  article-title: Combination Androgen Receptor Inhibition and Docetaxel in Metastatic Castration-sensitive Prostate Cancer: The Next Step in First-line Treatment?
  publication-title: Clin. Genitourin. Cancer
  doi: 10.1016/j.clgc.2020.05.003
– volume: 122
  start-page: 20
  year: 2017
  ident: ref_6
  article-title: The battle of “nano” paclitaxel
  publication-title: Adv. Drug Deliv. Rev.
  doi: 10.1016/j.addr.2017.02.003
– volume: 187
  start-page: 118
  year: 2014
  ident: ref_5
  article-title: Prostate cancer relevant antigens and enzymes for targeted drug delivery
  publication-title: J. Control. Release
  doi: 10.1016/j.jconrel.2014.05.035
– volume: 46
  start-page: 484
  year: 2016
  ident: ref_29
  article-title: Diagnostic and Therapeutic Strategies for Prostate Cancer
  publication-title: Semin. Nucl. Med.
  doi: 10.1053/j.semnuclmed.2016.07.002
– volume: 11
  start-page: 30
  year: 2014
  ident: ref_1
  article-title: Prostate cancer and the influence of dietary factors and supplements: A systematic review
  publication-title: Nutr. Metab.
  doi: 10.1186/1743-7075-11-30
– ident: ref_22
  doi: 10.3390/pharmaceutics14050964
– volume: 8
  start-page: 2812
  year: 2014
  ident: ref_13
  article-title: Optimized metal-organic-framework nanospheres for drug delivery: Evaluation of small-molecule encapsulation
  publication-title: ACS Nano
  doi: 10.1021/nn406590q
SSID ssj0000331839
Score 2.3736308
Snippet Prostate cancer (PC) is one of the common malignant tumors of the male genitourinary system. Here, we constructed PTX@ZIF-8, which is a...
SourceID doaj
pubmedcentral
proquest
gale
pubmed
crossref
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Enrichment Source
StartPage 1874
SubjectTerms Analysis
Androgens
Apoptosis
Cancer
Cancer therapies
Care and treatment
Cell culture
Chemotherapy
Clinical medicine
Drug delivery systems
Drugs
Efficiency
Ions
metal-organic framework
Nanoparticles
NMR
Nuclear magnetic resonance
Paclitaxel
Particle size
peptide dimer
Peptides
Polypeptides
Porous materials
Prevention
Prostate cancer
Tumors
Vehicles
Zinc
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1La9wwEBYlp15K33WTlCmU9BI365W1so7pNku2dMMeEgi9GD27hsUO8Qaaf5af1xnb-zAt5NKDD7YkbGnGo2-kmU-MfcpMGKjMidh6yWOCDLEJXMTKWG4GmdbSUnLy7GJ0fpV-vxbXO0d9UUxYSw_cDtxJ4A6VinOrRjo1qc78EGccdOmcMmnimzRfnPN2nKnGBnPSVdWm7HD0609uFtsl4rpBQZlMe5NRw9n_t2XemZr6YZM789DkOXvWAUg4bT_8BXviy5fsaN6-9_4YLrcJVfUxHMF8y019_4o97AQJQRXgosJbmGtLXN2__TL-UWnnHfycotbCzCM0j9t0TQuTdRwXoElGX7sLqYNZ5YqASBZoTRfmFCbjPHwraEUcdOnwgrMNqTi9dbqqYVouClPQFj-0DMqgf-kCwSrMKREFITCMSSNvYeyXy_o1u5qcXY7P4-7whtgKyVfx0Ctlg5IGAYpPhZdSi8Ra2vWR2qFfHIQZ2oHQaHG9loOQJBrRX5o4QShV8zdsr6xK_46Bl8Y4Y1HcwaLJCcokIiQoY8tpV9JFLF1LMbcdszkdsLHM0cMh4ef_FH7Evmya3bTUHo81-EoqsqlMzNzNA9TXvBv0_DF9jdhnUrCc7Ad-pNVdGgR2lZi48lMpVJKpLOMRO-jVxP_e9ovXKpp3dqfOEWzQjg36lRH7uCmmlhRLV_rqrqmTEvHgaBSxt61Gb7rEJYoAEXfEsp6u9_rcLymLRcNKTkz7KI7k_f8YpX32dIi9aOOiD9je6vbOHyL6W5kPzY_-ByulXMM
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Scholars Portal Journals: Open Access
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwELfGeOEF8U1goENC42UZTR3X8QNCo6xaEZ36sEoTL5G_skaqktF20vqf8edxl6QfEQMeqqq1rcS-8_l39t3PjL1PTNZRiROh9ZKHBBlCk3ERKmO56SRaS0vJyaPz3tkk_nYpLvfYmlChGcDFna4d3Sc1mc-Ob3-uPuOE_0QeJ7rsH6-n293fRQVwEhnfY_dxcZI0V0cN4q-MMyclVnUuz99bt1apisz_T5O9s2a14yl3FqjBI_awQZZwUqvCY7bniyfscFw_d3UEF9tMq8URHMJ4S1q9esp-7UQPQZnBeYk_YawtkXjf-ln4vdTOO_gxRHWGkcfhCus8TguDdYAXoK1GJ7yJtYNR6fIMIS7QZi-MKX7Gefia01Y56MLhB043bOP01OFyAcNimpuczv6hplYGfaVzRLEwpgwVxMbQJ1WdQ9_PZotnbDI4veifhc2tDqEVki_DrlfKZkoaRC4-Fl5KLSJr6ThIaocOcyZM13aERlPstexkUaQRFsaREwRfNX_O9ouy8C8ZeGmMM9bEUWbRFmXKRCKLUMaW03GlC1i8lmJqG8pzunljlqLrQ8JP7xR-wI43za5rzo__NfhCKrKpTJTd1R_l_CptBj3NuEPryLlVPR2bWCe-i9BJdaRT2AGfBOwDKVhKqo4vaXWTH4FdJYqu9EQKFSUqSXjADlo10SDYdvFaRdP1fEoRhdBRDjqcAXu3KaaWFGRX-PKmqhMTI2GvF7AXtUZvusQligCheMCSlq63-twuKfJpRVdOFPwojujVv9_rNXvQxe86FPqA7S_nN_4NAr6leVtN4d_E6Vsx
  priority: 102
  providerName: Scholars Portal
Title Development of Novel Paclitaxel-Loaded ZIF-8 Metal-Organic Framework Nanoparticles Modified with Peptide Dimers and an Evaluation of Its Inhibitory Effect against Prostate Cancer Cells
URI https://www.ncbi.nlm.nih.gov/pubmed/37514059
https://www.proquest.com/docview/2843100230
https://www.proquest.com/docview/2844095566
https://pubmed.ncbi.nlm.nih.gov/PMC10383971
https://doaj.org/article/f3d57833c96a4b4a8e2521907d9b41e8
Volume 15
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwhV3db9MwELdge-EF8U3GmIyExsvCkjqp7Se0lU4rolWENmniJfJX1khVUppOYv8Zfx53SZo2AsFDU7W2lTh3Pv98vvuZkPdCZ4EUNvaN48xHyODrjMW-1IbpQCjFDSYnT2fDy-voy0180zrcqjascmMTa0NtS4M-8lMwo-iLBsT8afnDx1OjcHe1PULjIdkHEyxg8bV_Pp4l3zovS8BQZ2WTusNgfX-6nG9dxVWNhgSPepNSzd3_p4XemaL64ZM789HFE_K4BZL0rJH8U_LAFc_IcdLc9_6EXm0Tq6oTekyTLUf1_XPyaydYiJYZnZXwkybKIGf3T7fwv5bKOku_T0B76dQBRPebtE1DLzbxXBRMM6y529A6Oi1tngGipejbpQmGy1hHP-foGaeqsPCh445cHO86WVd0UsxzneNWP22YlKm6VTmAVppgQgpAYTpCzVzRkVssqhfk-mJ8Nbr020McfBNztvYHTkqTSa4BqLgodpyrODQGd3-4srA-zmI9MEGswPI6xYMsDBWgwCi0MaJVxV6SvaIs3GtCHdfaaqOjMDNgejKpwzgDnWCG4e6k9Ui0kWJqWoZzPGhjkcJKB4Wf_lX4HvnYNVs2FB__a3COKtJVRobu-o9ydZu2Lz3NmAVjyJiRQxXpSAk3AKQkA24ldMAJj3xABUvRjsBDGtWmQ0BXkZErPeOxDIUUgnnksFcTxr_pF29UNG3tT5VuR4tH3nXF2BJj6gpX3tV1IiQgHA498qrR6K5LjIMIAHl7RPR0vdfnfkmRz2t2cmTcB3GEB_9-rjfk0QC-m8jnQ7K3Xt25t4Dv1vqoHcRHtX8ErtNI_AZFfVfj
linkProvider ProQuest
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6V9AAXxBtDgUGCcqmpnbWz3gNCbdqooUkUoVaquJh9uY0U2SVJBflTnPl5zMROUgsEpx58iHfX9mZmZ76ZnZll7E2is0AmNvaNE9wnyODrjMe-1IbrIFFKGEpO7g9aR6fRp7P4bIP9XObCUFjlUiYuBLUtDPnId1GMki8aEfPHy28-nRpFu6vLIzRKtjh28-9osk0_dA-Qvm-bzc7hSfvIr04V8E0s-MxvOilNJoVGzemi2Amh4tAY2o4QyqLBlsW6aYJYoShwSgRZGCqEJVFoY4JPiuNzb7HNiKMp02Cb-4eD4eeVVyfgtEZkmSrEuQx2Ly_WrunpAn0lIqopwcVZAX9qhGsqsR6ueU3_de6xuxVwhb2S0-6zDZc_YNvD8r3zHThZJ3JNd2Abhuua2POH7Ne14CQoMhgU-BOGylCN8B9u7PcKZZ2FL11cLdB3aBL4ZZqogc4yfgxQFaCNX4XyQb-wowwRNJAvGYYUnmMdHIzIEw8qt3jB4aqYOb21O5tCN78Y6RGFFkBZuRnUuRohSIYhJcAg9IY2rYQJtN14PH3ETm-EvI9ZIy9y95SBE1pbbXQUZgZFXSZ1GGfIg9xw2g21HouWVExNVVGdDvYYp2hZEfHTvxLfY-9Xwy7LkiL_G7BPLLLqTBXBFzeKyXla_elpxi0KX86NbKlIRypxTURmMhBW4gRc4rF3xGApyS38SKOq9AucKlUAS_dELMNEJgn32FatJ8obU29esmhaybtpul6dHnu9aqaRFMOXu-Jq0SeigoetlseelBy9mhIXSAJE-h5Larxem3O9JR9dLKqhU4V_JEf47N_f9YrdPjrp99Jed3D8nN1p4r0y6nqLNWaTK_cCseVMv6wWNLCvNy1DfgNryJGT
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV1Lb9NAEF6VVkJcEG8MBQYJyqUmdtbOeg8ItWmjhraRhVqp4mL25SZSZJcmFfSfIX4dM7HzsEBw6sGHeHdtb2Z25pvZmVnG3iQ6D2RiY984wX2CDL7OeexLbbgOEqWEoeTk40Hn4DT6dBafrbFf81wYCqucy8SZoLalIR95C8Uo-aIRMbfyOiwi3et9vPjm0wlStNM6P06jYpFDd_0dzbfJh_4e0vptu93bP-ke-PUJA76JBZ_6bSelyaXQqEVdFDshVBwaQ1sTQlk03vJYt00QKxQLTokgD0OFECUKbUxQSnF87i22IdAqCtbZxu7-IP288PAEnNaLrNKGOJdB62K4dFNPZkgsEVFDIc7ODfhTO6yox2bo5oou7N1jd2sQCzsV191na654wLbS6r3X23CyTOqabMMWpMv62NcP2c-VQCUocxiU-BNSZahe-A839o9KZZ2FL31cOXDs0Dzwq5RRA715LBmgWkB7vw7rg-PSjnJE00B-ZUgpVMc62BuRVx5UYfGC_UVhc3prfzqBfjEc6RGFGUBVxRnUuRohYIaUkmEQhkOXVsUldN14PHnETm-EvI_ZelEW7ikDJ7S22ugozA2KvVzqMM6RH7nhtDNqPRbNqZiZuro6HfIxztDKIuJnfyW-x94vhl1U5UX-N2CXWGTRmaqDz26Ul-dZ_adnObcoiDk3sqMiHanEtRGlyUBYiRNwicfeEYNlJMPwI42qUzFwqlQNLNsRsQwTmSTcY5uNnih7TLN5zqJZLfsm2XKleuz1oplGUjxf4cqrWZ-Iih92Oh57UnH0YkpcIAkQ9XssafB6Y87NlmI0nFVGp2r_SI7w2b-_6xW7jbIjO-oPDp-zO228VQVgb7L16eWVe4Ewc6pf1usZ2NebFiG_AQewlcg
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Development+of+Novel+Paclitaxel-Loaded+ZIF-8+Metal-Organic+Framework+Nanoparticles+Modified+with+Peptide+Dimers+and+an+Evaluation+of+Its+Inhibitory+Effect+against+Prostate+Cancer+Cells&rft.jtitle=Pharmaceutics&rft.au=Zhao%2C+Heming&rft.au=Gong%2C+Liming&rft.au=Wu%2C+Hao&rft.au=Liu%2C+Chao&rft.date=2023-07-01&rft.pub=MDPI+AG&rft.eissn=1999-4923&rft.volume=15&rft.issue=7&rft.spage=1874&rft_id=info:doi/10.3390%2Fpharmaceutics15071874&rft.externalDBID=HAS_PDF_LINK
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1999-4923&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1999-4923&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1999-4923&client=summon